Research Studies: Progressive Supranuclear Palsy

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

• This is a 5-year longitudinal investigating the best method of analysis to track patients with corticobasal syndrome (CBS), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), behavioral variant of frontotemporal degeneration (bvFTD), primary progressive aphasia (PPA), and other forms of frontotemporal lobar degeneration with the overall goal to prepare for treatment trials. The study will track familial FTD, sporadic FTD as well as asymptomatic participants with a strong history of familial FTD. The results will provide information about the value of novel imaging techniques for diagnosis and value of novel imaging techniques in comparison to biofluid biomarkers.

• The study will collect detailed clinical information, biofluids, and imaging data from participants at baseline and every year after that for 4 years or until the study concludes. A study partner/caregiver is required.

Ongoing Studies Currently Closed to Enrollment

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2 (4RTNI-2)

• This study is investigating the best method of analysis to track patients with corticobasal syndrome (CBS), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and oligo- or variant-progressive supranuclear palsy (o/vPSP). The results will provide information about the value of novel imaging techniques for diagnosis and value of novel imaging techniques in comparison to biofluid biomarkers.

• The study will collect detailed clinical information, biofluids, and imaging data from individuals with corticobasal degeneration and progressive supranuclear palsy. There will be one visit every six months for a year (a total of three visits over one year). Oligo- or variant- progressive supranuclear palsy, and healthy participants will be asked for an additional visit approximately one year after the third visit (adding up to four visits over two years). A study partner/caregiver is required.

NIO752: A Randomized, Participants, Investigator, Sponsor Blinded, Placebo-Controlled Study of Intrathecally Administered NIO752 in Participants with Progressive Supranuclear Palsy.

• The main purpose of study is to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of intracethally administered NIO752.